Wang, Ellen Q. http://orcid.org/0000-0001-5163-8993
Bukowski, Jack F.
Yunis, Carla
Shear, Charles L.
Ridker, Paul M.
Schwartz, Pamela F.
Baltrukonis, Daniel
Clinical trials referenced in this document:
Documents that mention this clinical trial
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
https://doi.org/10.1007/s40259-019-00375-0
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
https://doi.org/10.1016/j.ahj.2016.05.010
Funding for this research was provided by:
Pfizer
Article History
First Online: 16 September 2019
Compliance with Ethical Standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: The SPIRE-HR study was funded by Pfizer.
: Ellen Q. Wang, Carla Yunis, Pamela F. Schwartz, and Daniel Baltrukonis are full-time employees of Pfizer. Jack F. Bukowski and Charles L. Shear were employees of Pfizer at the time the study was conducted. Paul M. Ridker has acted as a consultant to Pfizer in relation to the SPIRE clinical trial program. Paul M. Ridker has received additional research grant support from Novartis, Amgen, and Kowa, and is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens.